

**Lyon and New York, September 7, 2016** - The Medicrea Group (Alternext Paris: FR0004178572 - ALMED), PEA-PME eligible, pioneering the development and manufacture of patient-specific analytical services and implant solutions for the treatment of spinal conditions, will announce its 2016 Half-Year Results on Thursday, 22 September, after market.

The other dates announced on the original schedule remain unchanged:

2016 Third Quarter sales

October 6, 2016\*
January 12, 2017\*

\*Subject to modification. After market.

## Next publication:

2016 Half-Year Results: September 22, after market.

## About Medicrea (www.medicrea.com)

The Medicrea Group is solely responsible for introducing personalized value-based healthcare solutions to the global complex spine market. The Company has driven innovation in Spine by focusing development on outcome-focused, market-disrupting technologies, including the growing UNiD™ Technology Platform of Patient-Specific Implants and Analytical Services, which received the first-ever FDA Clearance in November 2014. Medicrea has uniquely positioned itself outside of the traditional implant manufacturer's role in order to engage with each market player as a collaborator, offering customized implants to patients, personalized services to doctors and immediate cost-savings to providers. By leveraging its proprietary solutions with science, Medicrea is well-placed to improve spinal care efficiency for all stakeholders and continue charting clinical advancements.

## **Connect with Medicrea:**

FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

## **Contacts:**

Medicrea

Denys Sournac, Founder, Chairman and CEO <a href="mailto:dsournac@medicrea.com">dsournac@medicrea.com</a>

Fabrice Kilfiger, Chief Financial Officer <a href="mailto:fkilfiger@medicrea.com">fkilfiger@medicrea.com</a>
Tel: +33 (0)4 72 01 87 87





Medicrea is listed on ALTERNEXT Paris ISIN: FR 0004178572 - Ticker: ALMED

 <sup>2016</sup> Annual sales